Glaucoma Research Society Meeting

Seoul, Korea, 31 August – 3 September 2016

SCIENTIFIC PROGRAMME

THURSDAY 1 SEPTEMBER

Session 1: Predicting risk in glaucoma: biomarkers, bad genes and beyond

Chairs: J. Wiggs, D. Mackey

08.00   T. Aung          G-WAS. What IS the next big thing?
08.20   F. Grus (candidate) Fab biomarkers: future approaches for diagnosing glaucoma
08.40   J. Jeoung        Mitochondrial DNA as a risk predictor in glaucoma
09.00   D. Mackey        How can we fulfil the promise of modern genetics?
09.20   S. Orgul         Bad blood, reactive vessels and blood pressure
09.40   DISCUSSION
10.00   BREAK

Session 2: Comparing glaucoma to other neurodegenerative conditions

Chairs: F. Topouzis, S. Gandolfi

10.30   A. Clark          Hallmarks of neurodegenerative diseases - concepts and pathogenesis
10.50   N. Gupta          Vascular factors in neurodegenerative diseases and glaucoma
11.10   C. Burgoyne       Neural tissue under pressure: ONH – IOP vs CNS – CSF
11.30   N. Pfeiffer       Current treatment approaches in AD, PD etc - what can we learn?
11.50   P. Foster          Can RNFL thickness predict cognitive decline?
12.10   A. Coleman        Epidemiology of glaucoma and other NDD: comorbidities and risk

12:30   LUNCH
Session 3: The ageing optic nerve

Chairs: J. Crowston, G. Cioffi, C. Tham

13.30 H. Levkovitch-Verbin  Ageing and endogenous neuroprotection
13.50 L. Pasquale  Estrogen deficiency accelerates aging of the optic nerve
14.10 R. Ethier  Biomechanics and ageing
14.30 T. Yamamoto  Ageing and trabeculectomy
14.50 A. Robin  Managing the ageing epidemic in glaucoma
15.10 BREAK

Session 4: RGC degeneration and regeneration: where are we now?

Chairs: K. Martin, A. Clark, N. Gupta

15.40 H. Quigley  What is really happening at the optic nerve head?
16.00 K. Martin  Stimulating RGC regeneration
16.20 R. Ritch  Non-IOP dependent mechanisms in glaucoma
16.40 K. Park  Neuroprotection with nanomedicine
FRIDAY 2 SEPTEMBER

Session 5: From phenotyping to personalised medicine in glaucoma

Chairs: H. Levkovitch-Verbin, R. Thomas, J. Jonas

08.00  F. Topouzis  Risk assessment of the glaucoma patient
08.20  A. Khawaja (guest)  The association between risk factors and phenotype
08.40  L. Vijaya  Tailoring treatment to the patient
09.00  I. Goldberg  The challenges ahead

Session 6: Goldmann Lecture

09.20  Introduction – Franz Grehn
09.25  A. Heijl
10.00  BREAK

Session 7: What is needed to move to remote management of glaucoma?

Chairs: D. Friedman, M. He

10.30  D. Friedman  Basics of telemedicine for glaucoma
10.50  K. Mansour (guest)  Home tonometry
11.10  R. Sihota  Telemedicine in the developing world
11.30  G. Gazzard (guest)  Funding of telemedicine (how would it really work)

11:50 BUSINESS MEETING

12:45 LUNCH
**Session 8: Outcome measures for clinical trials**

*Chairs: D. Garway-Heath, L. Levin (guest), L. Schmetterer*

- **08.30** P. Ramulu (candidate)  QoL and patient-related outcomes
- **08.50** J. Caprioli  How much change is clinically relevant?
- **09.10** B. Chauhan  Rate of VF change as an outcome
- **09.30** D. Garway-Heath  Structure outcomes
- **09.50** C. Leung  DISCUSSION and CONCLUSIONS
- **10.10** BREAK

**Session 9: Candidate GRS Member Presentations**

*Chairs: F. Grehn, A. Heijl, C. Liu*

- **10.40** J. Wiggs  POAG genetics: Insights into a complex disease
- **11.00** R. Allingham  Eyes of Africa: Human diversity, genes, and glaucoma
- **11.20** T. Nakazawa  New approaches to Neuroprotection
- **11.40** K. Singh  Disease surveillance and glaucoma risk
- **12.00** A. Azuara-Blanco  Initial treatment of angle-closure glaucoma: should clear lens extraction replace laser peripheral iridotomy?

- **12.20** LUNCH
**Session 10: How will we be diagnosing and treating glaucoma in 2030?**

*Chairs: H. Quigley, N. Wang, K. Park*

13.20  P. Khaw               “10:10:10”
13.40  J. Crowston           Measuring neurorecovery in RGCs
14.00  J. Brandt             Future technologies: how will they change what we do?
14.20  F. Medeiros            The virtual future
15.40  DISCUSSION

15.00  BREAK

**Session 11: How do we know we are doing any good?**

*Chairs: A. Coleman, R. Wormald*

15.30  A. Tuulonen           Impact of glaucoma care – the societal perspective
15.50  P. Lee                 Impact of glaucoma care – the patient perspective
16.10  G. Cioffi              Effectiveness of care
16.30  H. Jampel              Patient experience under care

17.00  MEETING ADJOURNS